Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials. 

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.

Ruben Mesa, MD, discusses the latest advancements in the treatment paradigm for patients with myelofibrosis.

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.

Even in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.

Andrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.

The Hispanic population in the United States represents the fastest-growing segment of the population (expected to reach 30% of the nation's total by 2050), and faces significant cancer health disparities

Although bacillus Calmette-Guérin (BCG) therapy has significantly improved outcomes for patients with non–muscle invasive bladder cancer since its introduction nearly 40 years ago, there is a pressing need to enhance responses to BCG and to distinguish which patients would respond to treatment early on in the course of therapy.

Ian M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.